BeOne Medicines
ONC
#649
Rank
A$53.83 B
Marketcap
A$486.51
Share price
-2.56%
Change (1 day)
49.97%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeOne Medicines (ONC)

Revenue in 2025 (TTM): A$7.73 Billion

According to BeOne Medicines's latest financial reports the company's current revenue (TTM ) is A$7.49 Billion. In 2024 the company made a revenue of A$6.12 Billion an increase over the revenue in the year 2023 that were of A$3.60 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeOne Medicines from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$7.73 B26.34%
2024 A$6.12 B69.74%
2023 A$3.60 B73.45%
2022 A$2.08 B28.24%
2021 A$1.62 B303.92%
2020 A$0.40 B-34.32%
2019 A$0.61 B117.37%
2018 A$0.28 B-7.85%
2017 A$0.30 B20470.44%
2016 A$1.48 M-87.73%
2015 A$12.1 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Onconova Therapeutics
ONTX
A$0.34 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A$0.96 B-87.09%๐Ÿ‡บ๐Ÿ‡ธ USA